Dr. Menegatti’s work in Santa Barbara continues to have far reaching effects, as seen in the recent publication “A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer” in the Journal of Controlled Release.  Some of the ideas presented in this paper continue to inform our work and push the boundaries of drug delivery.

Congrats to Dr. Menegatti!